FEZOLINETANT (VEOZAH®)
















  • All comparisons were significantly better for fezolinetant
  • Reference [1]
Fezolinetant 45 mg
(N=174)
Placebo
(N=175)
Mean Frequency of Moderate to Severe Vasomotor Symptoms over 24 Hours
Baseline 10.4 10.5
Change from baseline
at 4 weeks
-5.4 -3.3
Change from baseline
at 12 weeks
-6.4 -3.9
Mean Severity of Moderate to Severe Vasomotor Symptoms over 24 Hours
Baseline 2.4 2.4
Change from baseline
at 4 weeks
-0.5 -0.3
Change from baseline
at 12 weeks
-0.6 -0.4



  • Reference [1]
Side effects reported in a 52-week trial
Side effect Fezolinetant 45 mg
(N=609)
Placebo
(N=610)
Abdominal pain 4.3% 2.1%
Diarrhea 3.9% 2.6%
Insomnia 3.9% 1.8%
Back pain 3.0% 2.1%
Hot flush 2.5% 1.6%
Hepatic transaminase elevation 2.3% 0.8%